Background: Extended field radiotherapy is a standard of care for low volume stage II testicular seminoma. We hypothesized that neoadjuvant carboplatin might reduce the recurrence risk.
introduction
Traditionally, small volume stage II testicular seminoma has been treated with radiotherapy alone with an extended field including both para-aortic and ipsilateral pelvic lymph nodes. With this policy, there is a relapse risk of 5%-11% [1, 2] . Though these recurrences can then be usually treated successfully with combination chemotherapy [3] [4] [5] , there is a concern over long-term complications from the intensity of their treatment, such as cardiovascular disease or second cancers [6, 7] .
A single dose of carboplatin (Hospira, UK) can reduce recurrence in stage I seminoma [8] , and in-field recurrence is rare after radiotherapy. We hypothesized that a similar reduction in metastatic relapse could be achieved in stage II seminoma if a single dose of carboplatin was added to radiotherapy. Additionally, it might be safe to reduce the radiation volume and dose. Therefore, we developed a programme which has been in clinical use since 1989 of treating patients with stage IIA and IIB seminoma with a single cycle of carboplatin followed 3-6 weeks later by radiotherapy to abdominal lymph nodes. Since 1996, we have consistently used a dose to achieve a blood concentration × time of carboplatin of 7 mg min/ml. This report is on the 51 patients with small volume stage II testicular seminoma we have treated in this way.
The initial strategy was to reduce the risk of recurrence and thus there is a need for salvage therapies. Subsequently, we also reduced the dose and extent of the radiation fields. The hypothesis was that the addition of a single cycle of carboplatin would be worthwhile to achieve these goals.
methods
All patients had a diagnosis of classical seminoma of the testis. Staging was by sequential analyses of blood levels of tumour markers alphafetoprotein, and beta human chorionic gonadotrophin (HCG), and by computed tomography (CT) scan of the thorax, abdomen and pelvis and classified by the maximum axial diameter using The Royal Marsden Hospital Classification such that IIA = node(s) <2 cm and IIB = node(s) 2-5 cm. In this classification, stage IIC = abdominal nodes >5 cm, stage III = supradiaphragmatic nodes and stage IV = extranodal metastases.
This analysis represents a retrospective audit of the standard treatment practice in our institution and was approved by The Royal Marsden Hospital Audit and Clinical Research Committees. Eligibility was generally that men had stage II seminoma with node metastasis up to 5 cm in diameter. If node involvement was equivocal, the scan was repeated 4-6 weeks later or was repeated with the associated PET analysis of fluorodeoxyglucose uptake (PET-CT scan). Ultimately classification as stage II disease was determined by collective judgement at a clinical/ radiology review meeting considering the size and position of 'abnormal' retroperitoneal nodes, supported in equivocal cases by repeat CT (n = 5) or PET scans (n = 5) or in one case by excision biopsy. Once classified as stage II, the number of nodes ≥1 cm in diameter was recorded as 'involved'.
Following signed consent, carboplatin was administered via a 1h infusion at a dose to achieve an area under the concentration × time curve of 7 mg min/ml (dose (mg) = (GFR + 25) × 7, where GFR = glomerular filtration rate measured by EDTA clearance). Oral antiemetics were prescribed before chemotherapy and during radiotherapy. Radiotherapy was initiated 3-6 weeks following carboplatin, patients were treated with anterior and posterior parallel-opposed portals shaped on virtual simulator CT planning. Initially, the fields encompassed both para-aortic and ipsilateral pelvic lymph nodes (dogleg field) extending superiorly to the lower border of the D10 vertebral body and inferiorly to the obturator fossa (n = 12). This field was treated to a dose of 30 Gy in 15 fractions following which the paraaortic nodes (D10-L5) were boosted by a further 5 Gy in 3 fractions. Since 2003, reflecting practice for stage I seminoma, the field has been restricted to the involved field, para-aortic strip (D11-L5 inc.) in 38 cases and ipsilateral pelvis in 1 case, and treated to a total dose of 30 Gy in 15 fractions. In the 39 patients in whom the radiation was given to the involved field to 30 Gy the follow-up was a median of 42 months (8-105 months).
Toxicity was recorded qualitatively and classified using descriptors from CTCAE version 3. Following treatment, patients were followed using a standard schedule [9] . Confidence intervals for recurrence risk were calculated as described by Newcombe [10] .
results
The age of 51 patients (Table 1) IIB though strictly classified as IIC with masses 6.2 and 7.0 cm in transverse diameter ( para-aortic and pelvic, respectively), and this was because the masses were positioned such that they could be irradiated without causing renal damage. Of the 19 patients with stage IIA disease the largest involved node in each individual ranged from 1.1-1.9 cm, (mean 1.5 cm); radiotherapy was to a dogleg field in 2 and para-aortic in 17. Three had 35 Gy and the rest had 30 Gy. Of the 32 patients treated as stage IIB disease, the largest involved node in each individual ranged from 2.0 to 7.0 cm (mean 3.3 cm and 17 cases had node size >3 cm. Twenty-two had para-aortic rather than dogleg fields and 24 had a dose of 30 Gy rather than 35 Gy. At the time of diagnosis of stage II disease, there was an elevated blood level of lactic dehydrogenase (LDH) in 12 of 48 patients and of HCG in 3 of 51 patients.
Follow-up was 8-151 months (median 55 months) from date of carboplatin. There have been no germ cell cancer recurrences. The 95% confidence intervals for relapse-free survival in all 51 patients are 93%-100%. Based on the 38 patients followed for more than 2 years (median 5.3 years) this result excludes with 95% confidence a relapse rate of >9%.
Toxicity has been mild and only short-term and is shown in Table 2 . In summary, there were four patients out of 50 assessed who developed haematological toxicity grade 3 (and none >3) ( platelet counts less than 50 × 10 9 per litre n = 4, total white blood count less than 2 × 10 9 per litre n = 3) none of whom suffered any clinical consequences. Platelet nadirs were 1-3 weeks after carboplatin. White blood count nadir was 2-6 weeks after carboplatin. Mild nausea occurred mainly during radiotherapy and was grade 3 in only 1 patient. Seven patients suffered grade 1-2 fatigue during radiotherapy.
discussion
This study has demonstrated a high progression-free survival in 51 patients with stage IIA and stage IIB testicular seminoma treated with a regimen composed of a single cycle of carboplatin (AUC7) followed by radiotherapy confined to the involved nodal region to a dose of 30 Gy in 15 fractions. A low recurrence risk minimizes the need for combination chemotherapy salvage, and the associated risks of myelosuppression, pneumonitis, neuropathy, hearing loss, renal damage, cardiac events and infertility, as well as second cancers. In our previous series [3] , 31 patients with stage IIA and IIB seminoma were treated with a similar protocol but with carboplatin at 400 mg/m 2 and a radiation dose of 35 Gy and 2 relapsed. A preliminary report on the first 29 patients in the current series followed for 0.6-7.5 years was published as a letter in 2009 [11] .
Our current regimen has very modest short-term toxicity. Long-term toxicity risks such as of second cancers are unlikely ever to be determined reliably given the rarity of this substage of disease, so will need to be estimated by extrapolation from larger series of patients who have had analogous treatments. In a recent national Dutch cohort of 2700 testicular cancer survivors, followed for a median of 17 years, the risk of second malignancy was increased by 2.6× after infradiaphragmatic radiotherapy and by 2.1× after combination chemotherapy [6] . This is consistent with the multinational Cancer Registry study of 40 567 testicular cancer survivors reported by Travis et al. [7] . However, the radiation carcinogenicity risks were based on an extended field which included pelvis as well as abdomen. Radiation risks can be reduced by using a smaller radiation field and an estimate of the reduced risk after para-aortic field compared with a full 'dogleg' field is a reduction of 48%-63% [12] .
Historical studies showing increased risk in those treated with both modalities may reflect a high total treatment burden such as for relapse. Carcinogenesis by chemotherapy has been linked to drug dose and class [13, 14] . Powles et al. [15] found no excess of second cancer after treatment with carboplatin but confidence intervals were wide and there have been insufficient long-term analyses to be confident of the lack of carcinogenesis by carboplatin or that this drug will not enhance radiation carcinogenesis.
Small volume stage II seminoma has traditionally been treated with radiotherapy (Table 3) , but in early years staging was by lymphography. The standard radiation field was extended to treat both para-aortic and ipsilateral upper pelvic nodes and doses ranged from 25 to 40 Gy. In the past, many centres also treated mediastinal or supraclavicular nodes. In a report from Toronto [1] on 79 patients, 8 (10%) relapsed; 4 were originally stage IIA and 4 stage IIB. A prospective registration study from 30 German centres [2] included 94 patients with stage IIA and IIB seminoma. After a median of 70 months, the 5-year relapse-free rate was 95% for stage IIA patients and 89% for stage IIB patients.
Platinum-based chemotherapy is also very effective for seminoma [16] [17] [18] . Most series (Table 4) indicate long-term progression-free survivals of >80% and survivals of >90%. Trials have shown that single agent carboplatin is less effective than cisplatin-based combination chemotherapy since it achieved only an ∼70% disease-free survival [19, 20] . The results of carboplatin in 108 patients with low-volume stage II showed 80% DFS [21] . In contrast, a trial of more standard EP chemotherapy in 72 patients showed a 90% 5-year PFS [22] .
Some centres have adopted a selective approach employing radiotherapy for stage IIA disease and recommending chemotherapy for those with more bulky nodes. For example, a retrospective analysis of 106 cases from Florence [4] included 89 treated with radiotherapy and the 5-year relapse-free survival was 94% for IIA and 72.5% for IIB. However, the radiotherapy included pelvis, abdomen, mediastinum and supraclavicular fossa in 42 patients. The Institut Gustave Roussy treated most stage IIA and IIB patients with radiotherapy and most stage IIC with chemotherapy [23] .
A number of treatment guideline publications have addressed management of small volume stage II seminoma [24] [25] [26] [27] . The European Association of Urology guidelines [27] recommend that radiotherapy is the standard treatment with para-aortic and ipsilateral iliac nodes to be treated to a dose of 30 Gy for IIA and 36 Gy for IIB stages. The case for recommending our approach for stage IIA and IIB seminoma is not only the evidence for efficacy, but also the expectation that long-term toxicity risks will be low. Carboplatin is a low toxicity drug with high level of activity against seminoma [15, 28] and is used with a low total dose. Though the radiotherapy component has both short-term gastrointestinal toxicity and a long-term risk of carcinogenesis, the risk should be lower than with more extended radiation fields and lower than with higher radiation doses. Also the approach may allow in the future evaluation of even further reduction of the extent of radiotherapy to less than a standard para-aortic field. A recent node mapping study [29] has for example demonstrated the rarity of node involvement above the renal vessels and if this region was not included there would be less irradiation of stomach and pancreas.
The results presented here demonstrate that our regimen is effective and has modest toxicity so is worthy of additional evaluation and development. As such, it is being further investigated as the recommended salvage schedule in the current MRC TE24 TRISST trial of stage I surveillance. http ://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=3820. 
